Dr. Minghua Bai 白明华
Chief Physician, Associate Professor
Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiotherapy and chemotherapy for colorectal, gastric, liver, biliary, pancreatic, urinary tract malignancies, soft tissue sarcoma, and lymphoma, including heavy ion therapy.
Dr. Bai holds a PhD in Oncology and serves as Deputy Director of the Abdominal Radiotherapy Department at Zhejiang Cancer Hospital. A former visiting scholar at Gunma University Heavy Ion Center in Japan, Dr. Bai leads research funded by CSCO-Gilead and provincial grants. Dr. Bai is a core member of the low-position rectal cancer sphincter-preserving team and has received provincial science and technology awards.
Professional roles
- Standing Committee Member, Radiotherapy Professional Committee, China Health Care Association
- Member, Gastrointestinal Tumor Group, Radiotherapy Branch, Chinese Medical Doctor Association
- Member, Urinary System Tumor Group, Radiotherapy Branch, Chinese Medical Doctor Association
- Member, Tumor Supportive Care Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Bai Minghua). Papers usually list the name as Minghua Bai or Bai M.
Selected publications
13 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Recent Pat Anticancer Drug Discov, 2026 (senior author): Ubiquitination-related Gene UBTD1 Mediates Poor Prognosis of Colorectal Cancer and Affects Colorectal Cancer Cell Proliferation and Ferroptosis. PubMed 39819411
- Cancer Lett, 2025 (first author): Distinct immunophenotypic profiles and neutrophil heterogeneity in colorectal cancer. PubMed 39993650
- Cancer Cell Int, 2025 (senior author): Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis. PubMed 40140870
- Cancer Cell Int, 2025 (senior author): Multi-omics analysis reveals that neutrophil extracellular traps related gene TIMP1 promotes CRC progression and influences ferroptosis. PubMed 39891145
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion